ClinicalTrials.gg
Status unknownNCT05348122Updated Jun 13, 2022

A Study of TG103 Injection in Type 2 Diabetes Subjects

A Phase 2 interventional study of TG103,Q2W and TG103,QW in Type 2 Diabetes Mellitus, sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-06-13.

Sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Diabetes Mellitus, Type 2 by CSPC Pharmaceutical Group Limited — 1 open to participants now, 2 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · CSPC Pharmaceutical Group Limited.

Planned enrollment
9th of 16
240 · median 247
Started
2022
the only one that year
Phase 2
5 of 16
1 open now
Registered
11th of 16
by date

Among the 16 studies in Diabetes Mellitus, Type 2 by CSPC Pharmaceutical Group Limited, this one is the 9th largest by planned enrollment, is the only one that started in 2022, is one of 5 in phase 2, and was the 11th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

1 of the 16 studies in Diabetes Mellitus, Type 2 by CSPC Pharmaceutical Group Limited is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Diabetes Mellitus, Type 2 by CSPC Pharmaceutical Group Limited, or all of them as a file.
02

Study summary

The primary objective of this trial is to evaluate the efficacy of different doses and frequencies of administration of TG103 injection in the treatment of type 2 diabetes.

Read the detailed description

This trial is a randomized, double-blind, placebo-parallel, Dulaglutide-controlled,multicenter phase Ⅱ clinical trial. The whole trial consists of two parts, Part A and Part B, and 240 subjects are planned to be enrolled. Part A will be divided into three groups: TG103 15 mg group, TG103 22.5 mg group and placebo group, given once every two weeks (Q2W); Part B will be divided into four groups: TG103 7.5mg dose group, TG103 15 mg dose group ,placebo group and Dulaglutide group, once a week (QW). After Part A enrollment is completed, Part B will continue to be enrolled. The trial will include a screening period of up to 2 weeks, an initiation period of 2 weeks, a double-blind treatment period of 16 weeks, and a safety follow-up period of 3 weeks.

03

Conditions studied

  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Clinical diagnosis of type 2 diabetes ;
  • Aged 18 to 75 years (inclusive), no gender limitation;
  • (BMI): 18.5≤BMI≤40;
  • Poor blood glucose control after diet and exercise alone without hypoglycemic drug treatment. Not treated with hypoglycemic drugs is defined as:Have not received hypoglycemic drugs before screening, or have received hypoglycemic drugs before screening, but have not received hypoglycemic drugs within 8 weeks before screening; and continuous use of insulin for no more than 14 days (except gestational diabetes) and/or the continuous use of another hypoglycemic drug for no more than 4 weeks within 1 year prior to screening;
  • must meet the following criteria:Screening: 7.5% ≤ HbA1c ≤ 11.0% (Local laboratory);Baseline: 7.0% ≤ HbA1c ≤ 10.5% (Central laboratory)
  • Subjects of must use reliable methods of throughout the study period and at least 3 months after the last dose to avoid pregnancy in female subjects or pregnancy in the male subject's partner;
  • Must be able to accurately use home glucose meter for self-glucose monitoring;
  • Be able to understand and follow the trial procedure, voluntarily participate in the trial and sign the form.

Exclusion criteria

Exclusion Criteria:

  • Type 1 diabetes;
  • Body weight change more than 5% within 1 month prior to screening;
  • Receive any of the following medications:Prior discontinuation of DPP-4 inhibitors or GLP-1 receptor agonists for efficacy, tolerability, and safety reasons;Systemic and growth hormone have been used within 8 weeks before screening or before randomization;
  • History of grade 3 hypoglycemia ≥2 times within 6 months prior to screening, or grade 3 hypoglycemia prior to screening to randomization;
  • Acute complications of diabetes, such as diabetic ketoacidosis and hyperglycemia, occurred ≥1 time within 6 months prior to screening, or prior to randomization;
  • Severe chronic complications of diabetes (e.g., proliferative diabetic retinopathy, severe diabetic neuropathy, diabetic foot, etc.) within 6 months prior to screening
  • History of acute or chronic pancreatitis prior to screening, or acute or chronic pancreatitis prior to randomization;
  • Subjects with gastric emptying abnormalities (e.g., gastric outlet obstruction), severe chronic gastrointestinal diseases (e.g., gastroparesis, inflammatory bowel disease, or intestinal obstruction) within 6 months prior to screening, or prior to randomization, long-term use of drugs that directly affect gastrointestinal motility, or gastrointestinal surgery that affects gastric emptying;
  • Any of the following cardiovascular events within 6 months prior to screening, or prior to randomization: unstable angina pectoris, myocardial infarction, coronary artery bypass grafting, coronary stent implantation, moderate or severe congestive heart failure ( grade III or IV), atrial or ventricular arrhythmia (e.g., atrial fibrillation, ventricular tachycardia, etc.), pacemaker or defibrillator implantation; Or subjects with Ⅱ or Ⅲ degree atrioventricular block, long syndrome or prolonged QTcF interval (QTcF: male >450 ms, female >470 ms) on 12-lead , or signs of heart disease with significant clinical symptoms at screening;
  • Hemorrhagic stroke or acute ischemic stroke disease occurred within 6 months prior to screening, or prior to randomization;
  • Having a history of serious respiratory tract, central nervous system (such as epilepsy, etc.) and psychiatric diseases (such as depression, anxiety, etc.) during screening; Or have a history of other diseases that may endanger the safety of the subject and that the investigator deems inappropriate for enrollment;
  • Any type of malignant tumor treated or untreated within 5 years prior to screening or prior to randomization (except clinically cured basal cell carcinoma or carcinoma in situ);
  • Severe or acute infection within 4 weeks prior to screening, or urinary tract or genital infection within 6 months prior to screening;
  • Having a significant blood system disease (e.g., aplastic anemia, myelodysplastic syndrome) or any disease causing hemolysis or red blood cell instability (e.g., malaria) at screening or prior to randomization;
  • Subjects with thyroid dysfunction that cannot be controlled by a stable drug dose at screening, or with clinically significant abnormalities in thyroid function examination results requiring drug treatment at screening ;
  • Personal or family history of medullary thyroid cancer (MTC) or type 2 multiple endocrine tumor syndrome at screening;
  • Systolic blood pressure ≥ 160mmHg or diastolic blood pressure ≥ 100mmHg at screening or before randomization;
  • Any of the following abnormalities during screening or prior to randomization of laboratory tests:FPG≥13.9 mmol/L; or AST≥2.5×;Total (TBiL) ≥1.5×ULN;Triglyceride >5.7 mmol/L;\<60 mL/(min*1.73 m\^2);Serum amylase and/or lipase ≥3×ULN (if lipase cannot be detected in some centers, amylase alone is acceptable); \<100 g/L;Calcitonin≥50 ng/L(pg/mL);
  • Serological examination: antibody or treponema pallidum antibody is positive; antibody is positive; surface antigen is positive, and the quantitative detection result of HBV DNA was higher than the lower limit of the detection reference range;
  • Known allergy to the test drug, Empagliflozin , or related ;
  • Subjects who underwent major surgery within 3 months prior to screening, or who lost more than 400 mL blood due to blood donation or other reasons within 3 months prior to screening;
  • Average alcohol intake more than 21 units of alcohol (male)/14 units of alcohol (female) per week within the 3 months prior to screening (1 unit ≈360 mL beer, or 45 mL spirits with 40% alcohol content, or 150 mL wine);
  • Subject participated in any drug or medical device clinical study within 3 months prior to screening (except for screening failure);
  • Pregnant or lactating female;
  • Not suitable for this study in the investigator's opinion.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    TG103, 15 mg,Q2W

    TG103 (15 mg) will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.

    Drug: TG103,Q2W

  • Experimental
    TG103, 22.5 mg,Q2W

    TG103 (22.5 mg) will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.

    Drug: TG103,Q2W

  • Placebo comparator
    Placebo,Q2W

    Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.

    Drug: Placebo,Q2W

  • Experimental
    TG103, 7.5 mg,QW

    TG103 (7.5 mg) will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.

    Drug: TG103,QW

  • Experimental
    TG103, 15 mg,QW

    TG103 (15 mg) will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.

    Drug: TG103,QW

  • Placebo comparator
    Placebo,QW

    Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.

    Drug: Placebo,QW

  • Active comparator
    Dulaglutide,QW

    Dulaglutide will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.

    Drug: Dulaglutide,QW

Interventions

  • TG103 injection will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.

    Also known as: TG103 injection, subcutaneous injection,Q2W

  • TG103 injection will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.

    Also known as: TG103 injection, subcutaneous injection,QW

  • DrugPlacebo,Q2W

    Placebo will be administered via subcutaneous injection once every two weeks in subjects with type 2 diabetes.

    Also known as: Placebo, subcutaneous injection,Q2W

  • DrugPlacebo,QW

    Placebo will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.

    Also known as: Placebo, subcutaneous injection,QW

  • Dulaglutide will be administered via subcutaneous injection once weekly in subjects with type 2 diabetes.

    Also known as: Dulaglutide,subcutaneous injection,QW

06

What researchers measure

Primary outcomes

  1. Changes in glycosylated hemoglobin (HbA1c) from baseline to week 17

    Changes in glycosylated hemoglobin (HbA1c) from baseline to week 17

    Time frame: Baseline through Day 113

Secondary outcomes

  1. Changes in glycosylated hemoglobin (HbA1c) from baseline to week 9

    Changes in glycosylated hemoglobin (HbA1c) from baseline to week 9

    Time frame: Baseline through Day57

  2. The percentage of HbA1c≤6.5% and the percentage of HbA1c≤7% at week 9 and 17

    The percentage of HbA1c≤6.5% and the percentage of HbA1c≤7% at week 9 and 17

    Time frame: Day57 and 113

  3. Change in fasting plasma glucose (FPG) from baseline to week 9 and 17

    Change in fasting plasma glucose (FPG) from baseline to week 9 and 17

    Time frame: Baseline through Day57 and 113

  4. Change in weight from baseline to week 9 and 17

    Change in weight from baseline to week 9 and 17

    Time frame: Baseline through Day57 and 113

  5. Mean postprandial blood glucose increment and change in mean postprandial blood glucose from baseline at 7-point Self-monitored Blood Glucose (SMBG) Profile.

    Mean postprandial blood glucose increment and change in mean postprandial blood glucose from baseline at 7-point Self-monitored Blood Glucose (SMBG) Profile.

    Time frame: Baseline through Day113

  6. Change in 7-point Self-monitored Blood Glucose (SMBG) Profile.

    Change in 7-point Self-monitored Blood Glucose (SMBG) Profile.

    Time frame: Baseline through Day113

  7. Change in blood lipids (triglycerides, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) from baseline to week 17.

    Change in blood lipids (triglycerides, total cholesterol, high-density lipoprotein cholesterol, and low-density lipoprotein cholesterol) from baseline to week 17.

    Time frame: Baseline through Day113

  8. Proportion of subjects receiving remedial therapy at week 17

    Proportion of subjects receiving remedial therapy at week 17

    Time frame: Day113

  9. Number of TEAEs and SAEs from baseline to week 17

    Number of TEAEs and SAEs from baseline to week 17

    Time frame: Day-14 through Day 113

  10. Ctrough will be measured once every 4 week until week 17

    Ctrough will be measured once every 4 week until week 17

    Time frame: Day1, 29, 57, 85 and 113

  11. The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (Nab).

    The occurrence of TG103 anti-drug antibodies (ADA) and neutralizing antibody (Nab).

    Time frame: Day1, 29, 57, 85, 113 and127

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2022; primary completion for Nov 2023, 16 months later.

Of 194 industry-sponsored phase 2 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 18. This study's planned 16 months is above that.

Counting every sponsor, half of 293 studies reached it within 15 months; a quarter within 11 and three quarters within 27.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2022
First posted
Apr 27, 2022
StartEst.
Jun 15, 2022
Primary completionEst.
Nov 1, 2023
CompletionEst.
Nov 1, 2023
Last update
Jun 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05348122
Responsible party
Sponsor
First posted
Apr 27, 2022
Start date
Jun 15, 2022 (estimated)
Primary completion
Nov 1, 2023 (estimated)
Completion
Nov 1, 2023 (estimated)
Last update
Jun 13, 2022

Study contacts

Huanhuan Gao
Contact
lcgaohuanhuan@mail.ecspc.com
+86-8031190343
Linong Ji
principal investigator · Peking University People's Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TG103

Start the discussion